Bio-Rad Q2 revenue beats analyst estimates on clinical diagnostics growth

Bio-Rad Laboratories

04/08/2026 21:27

Overview
US life science and diagnostics firm's Q2 revenue was flat yr/yr, beating analyst expectations
Company cited Life Science segment declines due to academic research market challenges
Bio-Rad repurchased about $32 mln in shares during the quarter

Outlook
Bio-Rad reaffirms 2026 non-GAAP, currency-neutral revenue outlook of -3% to +0.5%
Company expects 2026 non-GAAP operating margin of about 10% to 12%

Result Drivers
LIFE SCIENCE WEAKNESS - Co said Life Science segment sales fell due to ongoing challenges in the academic research market
CLINICAL DIAGNOSTICS GROWTH - Co said Clinical Diagnostics sales rose, led by quality systems, diabetes and blood typing products, partly offset by lower infectious disease product sales
DIGITAL PCR INSTRUMENTS - Co said digital PCR instrument revenue grew more than 20%

Company press release: ID:nBwb5b0rWa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
Beat
$651 mln
$623.99 mln (4 Analysts)
Q2 EPS
 
$13.85
 
Q2 Net Income
 
$371.40 mln
 
Q2 Gross Margin
 
53.1%
 

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Bio Rad Laboratories Inc is $310.00, about 7.4% below its August 3 closing price of $334.71
The stock recently traded at 36 times the next 12-month earnings vs. a P/E of 26 three months ago

Reuters Recommended Reads
Aug 4 - Revvity raises annual profit, revenue forecasts on strong diagnostics demand
Aug 4 - Waters lifts annual forecasts on strong lab-equipment and diagnostics demand
Aug 3 - GeneDx Q2 revenue beats analyst estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)